Summary: Based on the results of preclinic and phase I studies a cooperative study in six institutions in ČSSR was performed. 119 patients were included and 117 evaluated. The safety of application using the dose of 400 mg/m2 was proved. Positive therapeutic results were checked in ovarian, bladder and head/neck tumors. Myelotoxicity was therapy limiting, especially with patients previously treated. Further studies in lung cancer and including carboplatin in combination procedures in ovarian and head/neck cancer was warrnated.
Carboplatin, a clinical phase II study
